Skip to main content
An official website of the United States government

Doxorubicin Hydrochloride

Placeholder slot
 (DOK-soh-ROO-bih-sin HY-droh-KLOR-ide)

Doxorubicin hydrochloride is a type of chemotherapy drug called an anthracycline. It blocks an enzyme called topoisomerase II, which cuts and repairs tangled strands of DNA. This stops or slows the growth of cancer cells and other rapidly dividing cells.

FDA Approved
Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Doxorubicin hydrochloride is approved to be used alone or with other drugs to treat:

Doxorubicin hydrochloride is also being studied in the treatment of other types of cancer.

Doxorubicin hydrochloride is also available in a different form called doxorubicin hydrochloride liposome. For more information, see the Drug Information Summary for Doxorubicin Hydrochloride Liposome.

More About Doxorubicin Hydrochloride

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Doxorubicin Hydrochloride - A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Combination Chemo Helps People with Leiomyosarcoma Live Longer

Clinical Trials Accepting Patients

Find Clinical Trials for Doxorubicin Hydrochloride - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated:
Email